Dr. Naomi B. Haas, MDAssociate Professor of Medicine Director of the Prostate and Kidney Cancer Programs University of Pennsylvania, Abramson Cancer Center
A Phase 1-2 Dose-Escalation and Safety Study of ADXS-PSA Alone and of ADXS-PSA in Combination with KEYTRUDA®(MK-3475) in Patients with Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Naomi B. Haas, MD, associate professor of medicine and director of the Prostate and Kidney Cancer Program at the University of Pennsylvania Abramson Cancer Center, is the principal investigator of the clinical trial evaluating ADXS-PSA as a monotherapy and in combination with Keytruda® (pembrolizumab) in metastatic, castration-resistant prostate cancer (mCRPC).
- Dr. Haas described the multitude of changes in both the biologic understanding and treatment of CRPC that have transpired over the past several years, including the introduction of the first approved vaccine immunotherapy, sipuleucel-T – suggesting PC may well be an immunologically sensitive tumor.
- The PSA tumor antigen has been effectively leveraged by the Lm-LLO technology to generate the investigational agent, ADXS-PSA.
- Consistent with the rationale and preclinical evidence for combinatorial immunotherapy presented by Dr Khleif, Dr. Haas has worked with Advaxis to design a two-part, dose-escalation monotherapy and combination trial of ADXS-PSA with the anti-PD1 monoclonal antibody pembrolizumab in patients with CPRC who have received no more than 3 prior systemic treatments.
- The trial is expected to open to enrollment in 2015.